Zacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Post Quarterly Sales of $105.35 Million
Wall Street analysts forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will announce $105.35 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for NxStage Medical’s earnings, with the lowest sales estimate coming in at $103.40 million and the highest estimate coming in at $107.85 million. NxStage Medical reported sales of $96.22 million during the same quarter last year, which would suggest a positive year over year growth rate of 9.5%. The company is scheduled to announce its next quarterly earnings results on Monday, September 17th.
According to Zacks, analysts expect that NxStage Medical will report full-year sales of $430.57 million for the current financial year, with estimates ranging from $426.10 million to $435.91 million. For the next fiscal year, analysts anticipate that the company will post sales of $467.80 million per share, with estimates ranging from $467.30 million to $468.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover NxStage Medical.
Several research analysts recently commented on the company. BidaskClub upgraded NxStage Medical from a “sell” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research lowered NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Finally, ValuEngine lowered NxStage Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. NxStage Medical presently has an average rating of “Hold” and a consensus target price of $30.00.
NXTM traded down $0.04 on Friday, hitting $28.28. The company had a trading volume of 547,300 shares, compared to its average volume of 475,140. The firm has a market cap of $1.86 billion, a P/E ratio of -128.89 and a beta of -0.05. NxStage Medical has a 12-month low of $22.70 and a 12-month high of $28.75.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Further Reading: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.